logo BDSP

Base documentaire

  1. Is universal neonatal hemoglobinopathy screening cost-effetive ?

    Article - En anglais


    To determine whether and where universal neonatal screening for hemoglobinopathies, chiefly sickle-cell disease, could be performed at socially acceptable costs.


    We made projections of the cost-effectiveness of nonuniversal and universal sickle-cell disease screening throughout the United States.

    We then compared the cost-effectiveness of universal sickle-cell disease screening with that of universal phenylketonuria screening.

    Finally, we asked if « high-cost » states, that is, those in which the cost of finding a case of sickle-cell disease exceeded one half the cost of finding a case of phenylketonuria, could enhance their cost-effectiveness by joining demographically complementary states in screening cooperatives.

    Mots-clés Pascal : Hémoglobinopathie, Economie santé, Dépistage, Coût, Nouveau né, Homme, Etats Unis, Amérique du Nord, Amérique, Hémopathie, Anémie hémolytique

    Mots-clés Pascal anglais : Hemoglobinopathy, Health economy, Medical screening, Costs, Newborn, Human, United States, North America, America, Hemopathy, Hemolytic anemia

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 94-0487621

    Code Inist : 002B20G01. Création : 199501.